Every Form 4 that Arteris, Inc. (AIP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AIP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIP filings page.
Arteris, Inc. Chief Operating Officer Laurent R. Moll executed an open-market sale of common stock. On April 14, 2026, he sold 13,448 shares at a weighted average price of $20.0313 per share in multiple transactions.
After this sale, he directly holds 265,530 shares of Arteris common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 12, 2026, indicating the sales were pre-scheduled rather than opportunistic. Individual trade prices ranged from $19.90 to $20.22 per share.
Arteris, Inc. director Raman Chitkara sold shares in an open-market transaction. On this date, he sold 5,000 shares of common stock at a weighted average price of $20.0508 per share, with individual sale prices ranging from $20.00 to $20.13. After the sale, he directly holds 152,867 shares, indicating the transaction represents a small portion of his overall position.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported small open-market sales of company stock under a pre-set trading plan. He sold a total of 1,993 shares of common stock at a weighted average price around $19.90 per share and continues to hold 278,979 shares directly.
Arteris, Inc. director, President and CEO K. Charles Janac reported an indirect open-market sale of 70,000 shares of Common Stock at a weighted average price of $19.0398 per share. The shares were sold on April 8, 2026 by Bayview Legacy, LLC, an entity for which Janac serves as manager and has voting and dispositive power.
The sale was executed under a Rule 10b5-1 trading plan adopted on March 5, 2025. After the transactions reported, indirect holdings through Bayview Legacy, LLC were 9,119,071 shares, direct holdings were 196,729 shares, and 56,252 shares were held indirectly via the Charles and Lydia Janac Trust, for which Janac serves as trustee.
Bayview Legacy, LLC, a ten percent owner of Arteris, Inc., reported an open-market sale of 70,000 shares of Arteris common stock. The sale occurred on April 8, 2026 at a weighted average price of $19.0398 per share, with individual trade prices ranging from $18.67 to $19.43.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025 by K. Charles Janac, the manager of Bayview Legacy, LLC. Following the sale, Bayview Legacy, LLC indirectly held 9,119,071 shares of Arteris common stock, over which Janac is deemed to have voting and dispositive power.
Kunkel Joachim reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Joachim Kunkel received 899 shares of common stock as a fully vested restricted stock award. The award represents retainer fees he chose to take in shares instead of cash.
The grant was based on the average Arteris trading price of $15.98 over the period from February 20, 2026 through April 2, 2026. Following this award, he holds 69,627 shares of Arteris common stock directly. Kunkel elected to defer the receipt of these shares.
Arteris, Inc. director Claudia F. Munce received a grant of 860 shares of fully vested restricted common stock as part of her board retainer. The shares represent fees she chose to take in stock instead of cash, based on an average trading price of $15.98 for Arteris common stock between February 20, 2026 and April 2, 2026. After this compensation-related acquisition, she holds 101,711 shares directly. The filing notes she elected to defer the receipt of these shares.
Arteris, Inc. VP and Chief Financial Officer Nicholas B. Hawkins reported four open-market sales of common stock on April 2, 2026, totaling 4,870 shares at $17.6528 per share. According to the disclosure, these sales were executed under a mandatory “sell to cover” arrangement to fund tax withholding obligations arising from the release of restricted stock units, rather than discretionary trades. Following the final sale, Hawkins directly held 118,614 shares of Arteris common stock.
Arteris, Inc. Chief Operating Officer Laurent R. Moll reported multiple open-market sales of common stock primarily to cover taxes from the release of restricted stock units. He sold a total of 7,154 shares at prices between $17.65 and $18.23 per share and now directly holds 280,972 shares. According to the disclosure, these sales were required under the company’s equity plans as “sell to cover” transactions and were executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025, indicating they were not discretionary trades.
Arteris, Inc. President and CEO Charles Janac reported tax-related stock sales. He sold a total of 20,809 shares of common stock in open-market transactions on April 2 and April 6, 2026 at weighted average prices of about $17.6528 and $18.3394 per share.
The company explains these sales were made solely to satisfy his tax liability from the release of restricted stock units under a mandated “sell to cover” feature of its equity incentive plans, and are not discretionary trades. The filing also notes the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025.
After these trades, Janac holds 196,729 shares directly, plus indirect holdings of 9,189,071 shares through Bayview Legacy, LLC and 56,252 shares through the Charles and Lydia Janac Trust, where he has voting and dispositive authority.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported mandated sales of common stock to cover taxes from restricted stock unit vesting. On April 2, 2026, he sold a total of 3,649 shares at $17.6528 per share in open-market transactions.
The footnote explains these were "sell to cover" trades required under Arteris’ equity incentive plans to satisfy tax withholding obligations, and were not discretionary. After these sales, Alpern continues to hold 86,386 shares of Arteris common stock directly.
Arteris, Inc. President and CEO Charles K. Janac, through Bayview Legacy, LLC, reported open-market sales of 40,000 shares of Arteris common stock on March 25–26, 2026 at weighted average prices of $18.0309 and $18.3458. These trades were executed under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following the transactions, Bayview Legacy, LLC holds 9,189,071 shares indirectly, while separate holding entries show Janac with 217,538 shares held directly and 56,252 shares held through the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported selling a total of 40,000 shares of Arteris common stock in two open-market transactions. On March 25, it sold 7,012 shares at a weighted average price of about $18.03 per share, followed by 32,988 shares on March 26 at a weighted average price of about $18.35 per share.
The sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After these transactions, Bayview Legacy, LLC indirectly holds 9,189,071 Arteris common shares, so the sale represents a small portion of its overall position.
Arteris, Inc. President and CEO Charles K. Janac reported open-market sales of a total of 50,000 shares of common stock through Bayview Legacy, LLC on March 9–10, 2026. The shares were sold at weighted average prices of $14.2104 and $14.663 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After the sales, indirect holdings through Bayview Legacy, LLC were 9,229,071 shares, in addition to 217,538 shares held directly and 56,252 shares held via the Charles and Lydia Janac Trust.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of a total of 50,000 shares of common stock over two days. On March 9, 2026, it sold 41,000 shares at a weighted average price of $14.2104 per share, and on March 10, 2026 it sold 9,000 shares at a weighted average price of $14.6630. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted by K. Charles Janac as manager of Bayview Legacy, LLC. Following the transactions, Bayview Legacy, LLC held 9,229,071 Arteris common shares indirectly.
Arteris, Inc. director Saiyed Atiq Raza reported open‑market sales of 109,721 shares of common stock by the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust. The trust sold 106,031 shares on March 2, 2026 at a weighted average price of $17.2127 and 3,690 shares on March 4, 2026 at a weighted average price of $17.0153, under a pre‑arranged Rule 10b5‑1 trading plan.
After these transactions, the trust held 390,000 shares indirectly, and Raza also held 20,839 shares directly.
Arteris, Inc. director-related entity activity shows the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust selling a total of 90,279 shares of common stock in open-market transactions. These sales occurred on February 25–27, 2026 at weighted average prices around $17 per share under a pre-arranged Rule 10b5-1 trading plan.
After these indirect sales, the trust held 499,721 shares, while a separate direct holding for the reporting person stood at 20,839 shares of Arteris common stock as of February 25, 2026.
Arteris, Inc. major shareholder Bayview Legacy, LLC, a 10% owner, reported a bona fide gift transfer of 70,000 shares of Common Stock on February 20, 2026. Following this non-cash disposition, Bayview Legacy, LLC indirectly holds 9,279,071 Arteris shares, with voting and dispositive power exercised by its manager, K. Charles Janac.
Moll Laurent R reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. Chief Operating Officer Laurent R. Moll received an equity award of 37,553 shares of common stock on a grant or award basis, at a stated price of $0.0000 per share. After this award, his directly owned common stock holdings total 288,126 shares.
The footnote clarifies that the 37,553 shares are in the form of restricted stock units, each representing a contingent right to one share of common stock. These RSUs will vest as to 1/16 of the total on 4/1/2026, with the remainder vesting in equal quarterly installments thereafter, and they have no expiration date.
Arteris, Inc. reported that its VP and Chief Financial Officer, Nicholas B. Hawkins, acquired 41,217 restricted stock units as an equity award. Each RSU represents one share of common stock and vests 1/16 on 4/1/2026, then in equal quarterly installments. Following this grant, he holds 123,484 shares of common stock in total.
Alpern Paul L reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. reported that its VP and General Counsel, Paul L. Alpern, received an equity award of 32,385 restricted stock units (RSUs), each representing one share of common stock, at no cash cost per share. These RSUs will vest as to 1/16 of the total on April 1, 2026, then in equal quarterly installments thereafter, and have no expiration date. Following this grant, Alpern beneficially owns 90,035 shares of common stock, including the 32,385 RSUs.
Arteris, Inc. director and President and CEO K. Charles Janac reported multiple equity movements involving the company’s common stock. On February 18, 2026, he acquired 78,051 shares through a grant of restricted stock units, at a stated price of $0.0000 per share.
According to the footnotes, each RSU represents one share of common stock and will vest as to 1/16 of the total on April 1, 2026, then in equal quarterly installments thereafter, with no expiration date. After this grant, his directly held common stock position was 217,538 shares.
On February 20, 2026, Bayview Legacy, LLC, an entity for which Janac serves as manager with voting and dispositive power, made a bona fide gift of 70,000 common shares at a reported price of $0.0000 per share, leaving 9,279,071 shares indirectly held through that LLC. A separate line item shows 56,252 shares held indirectly by the Charles and Lydia Janac Trust, for which he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of the company’s common stock under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
The LLC sold 47,244 shares on February 9, 2026 at a weighted average price of $15.2053 per share and 2,756 shares on February 10, 2026 at a weighted average price of $15.0322 per share. After these transactions, it indirectly held 9,349,071 Arteris shares, with voting and dispositive power deemed to be held by manager K. Charles Janac.
Arteris, Inc. reported insider share sales by an entity managed by its President and CEO, Charles K. Janac. Bayview Legacy, LLC, over which he has voting and dispositive power, sold 47,244 shares of common stock on February 9, 2026 at a weighted average price of $15.2053 per share and 2,756 shares on February 10, 2026 at a weighted average price of $15.0322 per share. These sales were made under a Rule 10b5-1 trading plan adopted on March 5, 2025. After these transactions, Bayview Legacy, LLC held 9,349,071 shares indirectly for Janac. He also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported an automatic option exercise and share sale in Arteris, Inc. common stock. On February 2, 2026, he exercised options for 5,000 shares at an exercise price of $0.56 per share and then sold 5,000 shares of common stock at a weighted average price of $15.4753 per share.
The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 5, 2025. Following these transactions, Alpern beneficially owned 57,650 shares of Arteris common stock directly, and 65,000 derivative securities (stock options) remained outstanding with an exercise price of $0.56 per share, expiring on October 23, 2029.
Arteris, Inc. insider activity: An entity associated with President and CEO Charles Janac reported a planned sale of company stock. On January 15, 2026, Bayview Legacy, LLC sold 17,884 shares of Arteris common stock at a weighted average price of $17.8357 per share, under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following this sale, Bayview Legacy, LLC held 9,399,071 shares beneficially owned, over which Janac, as manager, is deemed to have voting and dispositive power.
Separately, Janac held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported selling 17,884 shares of Arteris common stock on January 15, 2026 at a weighted average price of $17.8357 per share. The trades were executed in multiple transactions at prices ranging from $17.75 to $18.04 and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
Following this sale, Bayview Legacy, LLC reported beneficial ownership of 9,399,071 Arteris shares held indirectly. K. Charles Janac is the manager of Bayview Legacy, LLC and is deemed to have voting and dispositive power over these shares, and he has separately filed his own Form 4 for the same transaction.
Arteris, Inc. insider activity shows a small planned share sale by an entity managed by its President and CEO, Charles K. Janac. On 01/13/2026, Bayview Legacy, LLC, over which Janac has voting and dispositive power, sold 2,116 shares of Arteris common stock at a weighted average price of $17.7901 per share under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following this transaction, Bayview Legacy, LLC held 9,416,955 shares indirectly for Janac, while he also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported an open-market sale of 2,116 shares of Arteris common stock on January 13, 2026. The shares were sold at a weighted average price of $17.7901 per share, in multiple trades between $17.7500 and $17.8100. The transaction was made under a Rule 10b5-1 trading plan adopted on March 5, 2025, meaning the sales followed a pre-set schedule. After this sale, Bayview Legacy, LLC indirectly beneficially owned 9,416,955 shares, and its manager, K. Charles Janac, is deemed to have voting and dispositive power over those shares.
Arteris, Inc. (AIP) President and CEO Charles Janac, a director and 10% owner, reported an automatic sale of common stock made under a pre-arranged Rule 10b5-1 trading plan. On January 8, 2026, Bayview Legacy, LLC, an entity managed by Janac, sold 50,000 shares of Arteris common stock at a weighted average price of $16.5831 per share, with individual sale prices ranging from $16.2150 to $17.3600.
Following this transaction, 9,419,071 shares of Arteris common stock were beneficially owned indirectly through Bayview Legacy, LLC. Janac also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Arteris, Inc. reported an insider share sale by Bayview Legacy, LLC, a 10% owner of the company. On January 8, 2026, Bayview Legacy, LLC sold 50,000 shares of Arteris common stock at a weighted average price of $16.5831 per share in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025. After this sale, Bayview Legacy, LLC beneficially owned 9,419,071 shares indirectly. K. Charles Janac is the manager of Bayview Legacy, LLC and is deemed to have voting and dispositive power over these shares, and he has separately filed his own Form 4 for the same transaction.
Arteris, Inc. reported that its VP and Chief Financial Officer, Nicholas B. Hawkins, sold 5,836 shares of common stock on January 7, 2026. The shares were sold under a pre-arranged Rule 10b5-1 trading plan that he adopted on June 4, 2025.
The sale was executed at a weighted average price of $17.272 per share, with individual trades occurring between $16.95 and $17.44. Following this transaction, Hawkins beneficially owns 82,267 shares of Arteris common stock, which includes 144 shares acquired on November 21, 2025 through the company’s Employee Stock Purchase Plan.
Arteris, Inc. insider trading report: President and CEO Charles Janac, who is also a director and 10% owner of Arteris, reported selling 11,145 shares of common stock on 01/06/2026 at a weighted average price of $16.9032 per share, in transactions executed between $15.86 and $17.65. The sale was made under a Rule 10b5-1 trading plan adopted on March 5, 2025.
After this sale, Janac directly beneficially owned 139,487 Arteris shares. He also had indirect beneficial ownership of 9,469,071 shares held by Bayview Legacy, LLC, where he is the manager and has voting and dispositive power, and 56,252 shares held by the Charles and Lydia Janac Trust, for which he serves as trustee.
Arteris, Inc. Chief Operating Officer Moll Laurent R reported a small insider sale of common stock. On January 6, 2026, the executive sold 1,420 shares at a price of $16.23 per share. After this transaction, Moll Laurent R directly held 250,573 shares of Arteris common stock. The sale was made under a Rule 10b5-1 trading plan that the reporting person adopted on March 12, 2025, indicating it was pre-arranged rather than a discretionary market-timed trade.
Arteris, Inc. director Joachim Kunkel reported receiving 910 shares of common stock as fully vested restricted stock on January 5, 2026. These shares represent retainer fees that he elected to take in stock instead of cash. The shares were acquired at a stated price of $0.00 per share, reflecting their nature as compensation rather than an open-market purchase. After this grant, Kunkel beneficially owned 68,728 shares of Arteris common stock in direct ownership. He also elected to defer the receipt of the shares, indicating that while the award is fully vested, delivery of the stock is postponed under a deferral arrangement.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported option exercises and stock sales in a Form 4. On January 5, 2026, he exercised options for 2,500 shares of common stock at an exercise price of $9.28 per share, increasing his holdings to 64,468 shares directly owned.
On the same day, he sold 2,500 shares at $16.00, and on January 6, 2026 he sold an additional 4,318 shares at a weighted average price of $16.8913, with actual sale prices ranging from $15.86 to $17.62. After these transactions, he directly owned 57,650 shares of Arteris common stock. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on June 5, 2025, and that the options for 2,500 shares vest quarterly over 16 quarters starting April 1, 2025 and expire on February 20, 2035.
Arteris, Inc. President and CEO Charles K. Janac, who is also a director and 10% owner, reported sales of company common stock on January 2, 2026. He sold 3,185, 1,618, and 3,020 shares of Arteris common stock at a price of $15.4471 per share, with the filing stating that the shares were sold to satisfy his tax liability arising from the release of restricted stock units. After these transactions, he directly beneficially owned 150,632 shares of common stock. The filing also reports indirect beneficial ownership of 9,469,071 shares through Bayview Legacy, LLC, where he is the manager with voting and dispositive power, and 56,252 shares held by the Charles and Lydia Janac Trust, for which he serves as trustee.
Arteris, Inc. director K. Charles Janac reported an indirect sale of company stock executed under a pre-arranged trading plan. On December 4, 2025, an entity he manages, Bayview Legacy, LLC, sold 40,000 shares of Arteris common stock at a weighted average price of $16.4618 per share under a Rule 10b5-1 plan adopted on March 5, 2025. Following this transaction, Janac beneficially owned 9,599,071 shares of Arteris common stock indirectly through Bayview Legacy, LLC.
Arteris, Inc. (AIP) — Form 4 insider transaction: On 11/10/2025, a reporting person sold 50,000 shares of common stock at a weighted average price of $14.7366, coded as an open-market sale (S). The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2025.
Following the transaction, the reporting person beneficially owned 9,639,071 shares, held indirectly through Bayview Legacy, LLC. The filer is identified as a Director. The price range for the sales was $14.34 to $14.95, with details available upon request.
Arteris, Inc. (AIP) disclosed an insider transaction: Chief Operating Officer Moll Laurent R. sold 32,775 shares of common stock on 11/05/2025 at a weighted average price of $15.4233. The shares were sold in multiple trades within a price range of $14.90–$15.90.
The transactions were executed under a Rule 10b5-1 trading plan adopted on March 12, 2025. After the sale, the reporting person beneficially owns 311,110 shares directly.
Arteris, Inc. (AIP) reported an insider transaction by its VP and General Counsel. On 11/03/2025, the officer exercised 5,000 options at $0.56 per share (code M) and sold 5,000 shares at a weighted average price of $13.162 (code S), with sale prices ranging from $12.98 to $13.59. The trades were made under a Rule 10b5‑1 trading plan adopted on June 5, 2025. Following the transactions, the officer reported 65,960 shares of common stock held directly and 80,000 derivative securities remaining. The option underlying the exercised shares expires on 10/23/2029, with vesting that began in 2020.
Arteris, Inc. reporting person Janac K. Charles disclosed insider sales executed under a 10b5-1 trading plan adopted on 03/05/2025. The filing shows a weighted-average sale of $13.0742 for 50,000 shares sold on 10/08/2025. After the reported transactions, the reporting person is listed as having 9,689,071 shares beneficially owned indirectly through Bayview Legacy, LLC, and additional holdings are noted through the Charles and Lydia Janac Trust. The report was signed by an attorney-in-fact on 10/10/2025. The sale is identified as made pursuant to a pre-established trading plan and the filing discloses the range of execution prices between $13.00 and $13.20.
Arteris, Inc. (AIP) reporting person Bayview Legacy, LLC (managed by K. Charles Janac) sold 50,000 shares of common stock on 10/08/2025 under a pre-existing 10b5-1 trading plan. The weighted average sale price was $13.0742 (individual trades ranged from $13.00 to $13.20). After the sale, Bayview Legacy, LLC is reported to beneficially own 9,689,071 shares indirectly through the manager relationship. The filing notes that Janac separately filed an individual Form 4 to report the same transaction and confirms he is deemed to have voting and dispositive power over the shares held by Bayview Legacy, LLC.
Insider sale under 10b5-1 plan. The filing shows that Nicholas B. Hawkins, Vice President and Chief Financial Officer of Arteris, Inc. (AIP), sold 6,421 shares of common stock on 10/07/2025 at a weighted average price of $13.2073 per share. The report states the sales were executed under a 10b5-1 trading plan adopted on 06/04/2025. After the transactions, Hawkins beneficially owned 93,590 shares. The filer notes the sale prices ranged from $12.85 to $14.11 and offers to disclose per‑price quantities on request.
Arteris, Inc. director, president and CEO Janac K. Charles reported sales under a pre-established 10b5-1 plan. On 10/06/2025 the reporting person sold 5,755 shares at a listed price of $14 and sold an additional 100,000 shares at a weighted average price of $13.1045 (individual trades ranged from $12.50 to $13.85). After these transactions, direct beneficial ownership is reported as 161,759 shares and indirect ownership through entities is 9,739,071 shares. The filing notes the sales were executed pursuant to a trading plan adopted on 03/05/2025.
Arteris, Inc. insider filing reports that Bayview Legacy, LLC, an entity managed by K. Charles Janac, sold 100,000 shares of Arteris common stock on 10/06/2025 under a 10b5-1 trading plan. The sales were executed in multiple transactions at weighted-average price $13.1045, with trade prices ranging from $12.50 to $13.85. After the disposition, Bayview Legacy, LLC is reported to beneficially own 9,739,071 shares, and Janac is deemed to have voting and dispositive power as the manager. Janac also filed a separate Form 4 reporting the same sale in his individual capacity.
Arteris, Inc. director Antonio J. Viana reported insider sales on 10/06/2025. The filing shows a sale of 11,841 shares of common stock at a price of $14 and an additional disposal of 20,840 common shares. After these transactions the reporting person is listed as beneficially owning 184,620 shares indirectly through the Viana Family Trust. The sales were made under a pre-existing Rule 10b5-1 trading plan that the reporting person adopted on 06/10/2025, and the Form 4 was signed by an attorney-in-fact on 10/06/2025. The filing presents routine, planned insider disposals rather than unscheduled or ad-hoc trades.
Insider sale summary: A Form 4 shows that Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), sold a total of 7,627 shares of common stock in two days, 10/02/2025 and 10/03/2025, to satisfy tax obligations arising from the release of restricted stock units and under a previously adopted trading plan. The reported weighted average sale prices ranged from $10.81 to $11.30 with the weighted averages disclosed as $10.9208 and $11.082.
After these dispositions, the reporting person beneficially owned 65,960 shares directly. One tranche of the sales was executed pursuant to a 10b5-1 trading plan adopted on 06/05/2025, and the filer states the sales served to cover tax liabilities from released restricted stock units.
Arteris, Inc. (AIP) reported insider transactions by its Chief Operating Officer. On 10/02/2025, the COO sold 1,885, 891, and 1,926 shares at $10.9208 per share, including shares sold to satisfy tax liabilities from restricted stock unit release. Additional sales under a Rule 10b5-1 trading plan adopted on March 12, 2025 included 19,060 shares at a weighted average price of $10.9908 on 10/02/2025, 1,554 shares at $11.0866 on 10/03/2025, and 17,200 shares at $12.6598 on 10/06/2025.
Following these transactions, the COO beneficially owned 343,885 shares directly.
Arteris (AIP) — Form 4 insider activity: President and CEO K. Charles Janac, who is also a Director and 10% Owner, reported open‑market sales on 10/02/2025 and 10/03/2025. The filing lists sales of 2,767, 1,613, and 2,767 shares at $10.9208, and a separate sale of 11,821 shares at a weighted average price of $11.0705 (with individual trades between $10.80 and $11.29).
One set of shares was sold to satisfy the reporting person’s tax liability from an RSU release, and another transaction was made under a Rule 10b5‑1 trading plan adopted on March 5, 2025. Following the reported transactions, direct holdings were shown as 167,514 shares. Indirect holdings were listed as 9,839,071 shares through Bayview Legacy, LLC and 56,252 shares held by the Charles and Lydia Janac Trust.